MAP2K7 and thyroid gland carcinoma: In addition to melanoma, current clinical trials are investigating MEK inhibitors for intraocular melanoma, multiple myeloma, colorectal carcinoma, thyroid carcinoma, leukemia, and other soft tissue malignancies.